Edition:
India

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

61.71USD
18 May 2018
Change (% chg)

$0.65 (+1.06%)
Prev Close
$61.06
Open
$61.02
Day's High
$61.87
Day's Low
$60.94
Volume
3,023,661
Avg. Vol
1,814,903
52-wk High
$64.60
52-wk Low
$42.88

Chart for

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Overall

Beta: 1.57
Market Cap(Mil.): $95,559.38
Shares Outstanding(Mil.): 1,737.44
Dividend: 0.26
Yield (%): 1.93

Financials

  ABT.N Industry Sector
P/E (TTM): 84.45 30.95 32.75
EPS (TTM): 0.65 -- --
ROI: 2.24 14.84 14.38
ROE: 4.07 16.34 16.07

BRIEF-Abbott Expands Cardiac Arrhythmias Portfolio With FDA Clearance Of Advanced Mapping Catheter

* ABBOTT EXPANDS CARDIAC ARRHYTHMIAS PORTFOLIO WITH FDA CLEARANCE OF ADVANCED MAPPING CATHETER

03 May 2018

UPDATE 2-Outgoing Smith & Nephew CEO signs off with a downgrade

* Shares fall 7 pct (Adds CEO comments, analyst reaction, shares)

03 May 2018

BRIEF-Abbott's Xience Sierra Heart Stent Receives National Reimbursement In Japan

* ABBOTT'S XIENCE SIERRA™ HEART STENT RECEIVES NATIONAL REIMBURSEMENT IN JAPAN TO TREAT PEOPLE WITH CORONARY ARTERY DISEASE Source text for Eikon: Further company coverage:

02 May 2018

BRIEF-Abbott Laboratories Says Shareholders Rejected Proposal Requesting Board Of Directors Adopt Policy That Board Chairman Be Independent Director

* ABBOTT LABORATORIES SAYS SHAREHOLDERS REJECTED PROPOSAL REQUESTING CO'S BOARD OF DIRECTORS ADOPT POLICY THAT BOARD CHAIRMAN BE INDEPENDENT DIRECTOR Source text: (https://bit.ly/2KqCwQY) Further company coverage:

01 May 2018

BRIEF-Abbott Laboratories - Co, Sanquin Sign Multiple-Year Contract For Supply Of Primary Serological Equipment And Consumables

* ABBOTT LABORATORIES - CO, SANQUIN SIGN MULTIPLE-YEAR CONTRACT FOR SUPPLY OF PRIMARY SEROLOGICAL EQUIPMENT AND CONSUMABLES Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

23 Apr 2018

Abbott sticks to earlier forecasts, disappoints investors

Abbott Laboratories' just beat expectations for first quarter profits and revenue on Wednesday but stuck to a full-year profit forecast some investors had expected would be raised, sending the healthcare company's shares lower.

18 Apr 2018

Abbott sticks to earlier forecasts, disappoints investors

Abbott Laboratories' just beat expectations for first quarter profits and revenue on Wednesday but stuck to a full-year profit forecast some investors had expected would be raised, sending the healthcare company's shares lower.

18 Apr 2018

UPDATE 3-Abbott sticks to earlier forecasts, disappoints investors

* Analysts cite disappointment on whisper numbers among investors

18 Apr 2018

BRIEF-Abbott Q1 GAAP Earnings Per Share $0.23 From Continuing Operations

* Q1 GAAP EARNINGS PER SHARE $0.23 FROM CONTINUING OPERATIONS

18 Apr 2018

Abbott Labs' quarterly revenue rises 16.7 percent

April 18 Abbott Laboratories on Wednesday posted a 16.7 percent rise in quarterly revenue, helped by strong demand for its newer devices.

18 Apr 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $124.24 +0.39
Pfizer Inc. (PFE.N) $35.64 -0.07
Novartis AG (NOVN.S) CHF77.00 -0.64
Merck & Co., Inc. (MRK.N) $59.14 +0.07
Sanofi SA (SASY.PA) €66.44 +0.32
AstraZeneca plc (AZN.L) 5,241.00 -104.00
GlaxoSmithKline plc (GSK.L) 1,488.20 -2.20
Eli Lilly And Co (LLY.N) $82.07 +0.41
Amgen, Inc. (AMGN.OQ) $176.30 +1.65
Boston Scientific Corporation (BSX.N) $30.45 +0.13

Earnings vs. Estimates